top banner imagetop banner mobile image
Press Release
<< Back
TherapeuticsMD Announces Third Quarter 2016 Financial Results

- Topline phase 3 data for TX-001HR Replenish Trial on track for fourth quarter of 2016 -

- TX-004HR PDUFA target action date of May 7, 2017 -

BOCA RATON, Fla.--(BUSINESS WIRE)--Nov. 3, 2016-- TherapeuticsMD, Inc. (NYSE MKT:TXMD), an innovative women’s healthcare company, today announced its third quarter financial results for the quarter ended September 30, 2016.

Third Quarter and Recent Developments

  • Announced acceptance of a New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA) for TX-004HR (conditionally-approved trade name Yuvvexy™), the company’s investigational applicator-free estradiol vaginal softgel capsule for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause. The NDA is supported by the complete TX-004HR clinical program, including positive phase 3 results with all three doses of TX-004HR (4 mcg, 10 mcg and 25 mcg) that were evaluated in the Rejoice Trial. The FDA’s Prescription Drug User Fee Act (PDUFA) target action date for the NDA is May 7, 2017.
  • Anticipate topline results in the fourth quarter of 2016 for the ongoing Replenish Trial, a phase 3 clinical trial of the company’s TX-001HR product candidate, which, if approved, would be the first and only FDA-approved bio-identical combination of estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms due to menopause.
  • Net revenue from the company’s prescription prenatal vitamin business increased 7 percent to approximately $5.5 million for the third quarter of 2016, compared with approximately $5.2 million for the third quarter of 2015.
  • Net loss was approximately $25.0 million for the third quarter of 2016, compared with approximately $19.5 million for the third quarter of 2015.
  • Ended the quarter with approximately $147.5 million in cash and no debt.
  • Supported nine presentations at annual meetings of the International Menopause Society (IMS) and North American Menopause Society (NAMS), including reports on the positive results from the TX-004HR clinical development program and new data that further identify women’s perceptions of VVA and available treatment options.
  • Grew the company’s intellectual property portfolio to a current total of 149 patent filings, including 82 international filings, with 17 issued U.S. patents.
  • Strengthened relationships with medical, pharmacy, patient and industry organizations internationally.

“We are making excellent progress this year advancing our pipeline and enhancing our commercial capabilities focused on women’s health. During the quarter, we successfully completed the submission of our NDA for TX-004HR as a novel treatment for moderate to severe dyspareunia, a symptom of VVA due to menopause, and we continued ongoing pre-commercialization activities for this important product,” said TherapeuticsMD CEO Robert G. Finizio. “We now eagerly await the topline data from our Replenish Trial for TX-001HR in the fourth quarter of 2016, our second novel hormone therapy program, which, if approved, would be the first and only FDA-approved bio-identical combination of estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms due to menopause.”

Summary of Third Quarter 2016 Financial Results

Net revenue from the company’s prescription prenatal vitamins increased 7 percent to approximately $5.5 million for the third quarter of 2016 from approximately $5.2 million for the prior year’s quarter.

Cost of goods sold was approximately $1.2 million for the third quarter of both 2016 and 2015.

Total operating expenses for the third quarter of 2016 included research and development (R&D) expenses and sales, general and administrative expenses (SG&A). R&D expenses during the third quarter of 2016 were approximately $14.7 million compared to approximately $16.4 million during the prior year’s quarter, reflecting a decline in the company’s clinical trial costs. SG&A expenses for the third quarter of 2016 were approximately $14.7 million compared with approximately $7.1 million for the prior year’s quarter. Higher SG&A expenses during the third quarter of 2016 were primarily due to an increase in the company’s sales, marketing and regulatory personnel to support future commercialization of the company’s pipeline products.

Net loss for the third quarter of 2016 was approximately $25.0 million, or $0.13 per basic and diluted share, compared with approximately $19.5 million, or $0.11 per basic and diluted share, for the third quarter of 2015.

At September 30, 2016, cash on hand was approximately $147.5 million, compared with approximately $64.7 million at December 31, 2015.

Conference Call Today

As previously announced, TherapeuticsMD will host a conference call today to discuss these financial results and provide a business update. Details for the call are:



Thursday, November 3, 2016


4:30 p.m. EDT

Telephone Access (US):


Telephone Access (International):


Access Code for All Callers:


Additionally, a live webcast can be accessed on the company’s website,, in the “Investors & Media” section. A digital recording of the conference call will be available for replay beginning two hours after the call's completion and for at least 30 days with the dial-in 855-859-2056 or international 404-537-3406 and Conference ID: 99198056.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA™ technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The company’s clinical development pipeline includes two phase 3 products. The company also manufactures and distributes branded and generic prescription prenatal vitamins as well as over-the-counter vitamins under the vitaMedMD® and BocaGreenMD® brands. More information is available at the following websites:,, and

Forward-Looking Statements

This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize its hormone therapy drug candidates and obtain additional financing necessary therefor; whether the FDA will approve the company’s new drug application for its TX-004HR product candidate and whether any such approval will occur by the PDUFA date; the length, cost and uncertain results of the company’s clinical trials; the potential of adverse side effects or other safety risks that could preclude the approval of the company’s hormone therapy drug candidates; the company’s reliance on third parties to conduct its clinical trials, research and development and manufacturing; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership. PDF copies of the company’s historical press releases and financial tables can be viewed and downloaded at its website:

September 30, 2016 December 31, 2015
Current Assets:
Cash $ 147,534,065 $ 64,706,355
Accounts receivable, net of allowance for doubtful accounts
of $113,034 and $81,910, respectively 5,033,298 3,049,715
Inventory 843,398 690,153
Other current assets   2,693,475     2,233,897  
Total current assets   156,104,236     70,680,120  
Fixed assets, net   460,546     198,592  
Other Assets:
Intangible assets, net 2,118,378 1,615,251
Prepaid expense - 1,109,883
Security deposit   139,036     125,000  
Total other assets   2,257,414     2,850,134  
Total assets $ 158,822,196   $ 73,728,846  
Current Liabilities:
Accounts payable $ 4,224,419 $ 3,126,174
Other current liabilities   8,243,421     7,539,526  
Total current liabilities   12,467,840     10,665,700  
Total liabilities   12,467,840     10,665,700  
Commitments and Contingencies - See Note 15
Stockholders' Equity:
Preferred stock - par value $0.001; 10,000,000 shares authorized;
no shares issued and outstanding - -
Common stock - par value $0.001; 350,000,000 shares authorized;
196,580,212 and 177,928,041 issued and outstanding, respectively 196,580 177,928
Additional paid in capital 433,023,801 282,712,078
Accumulated deficit   (286,866,025 )   (219,826,860 )
Total stockholders' equity   146,354,356     63,063,146  
Total liabilities and stockholders' equity $ 158,822,196   $ 73,728,846  
    Three Months Ended               Nine Months Ended
September 30, September 30,
  2016       2015     2016       2015  
Revenues, net $ 5,535,685 $ 5,190,175 $ 14,869,023 $ 14,513,158
Cost of goods sold   1,237,446     1,193,965     3,475,997     3,270,695  
Gross profit   4,298,239     3,996,210     11,393,026     11,242,463  
Operating expenses:
Sales, general, and administration 14,721,710 7,060,944 35,019,268 20,089,998
Research and development 14,664,123 16,421,753 43,602,333 58,789,302
Depreciation and amortization   40,460     16,548     84,319     44,400  
Total operating expense   29,426,293     23,499,245     78,705,920     78,923,700  
Operating loss   (25,128,054 )   (19,503,035 )   (67,312,894 )   (67,681,237 )
Other income:
Miscellaneous income 109,942 27,630 265,879 71,728
Accreted interest   2,451     2,760     7,850     15,162  
Total other income   112,393     30,390     273,729     86,890  
Loss before taxes (25,015,661 ) (19,472,645 ) (67,039,165 ) (67,594,347 )
Provision for income taxes   -     -     -     -  
Net loss $ (25,015,661 ) $ (19,472,645 ) $ (67,039,165 ) $ (67,594,347 )
Net loss per share, basic and diluted $ (0.13 ) $ (0.11 ) $ (0.34 ) $ (0.39 )
Weighted average number of common
shares outstanding   196,502,327     177,206,168     195,912,173     171,589,595  
    Nine Months Ended
September 30, 2016   September 30, 2015
Net loss $ (67,039,165 ) $ (67,594,347 )
Adjustments to reconcile net loss to net cash flows used in
operating activities:
Depreciation of fixed assets 45,759 22,104
Amortization of intangible assets 38,560 22,296
Provision for doubtful accounts 2,261,568 37,163
Share-based compensation 13,385,215 4,740,906
Changes in operating assets and liabilities:
Accounts receivable (4,245,151 ) (1,549,532 )
Inventory (153,245 ) 312,054
Other current assets 379,930 (621,923 )
Other assets - (15,162 )
Accounts payable 1,098,245 (1,025,504 )
Deferred revenue - (522,613 )
Other current liabilities 703,895 2,546,138
Other long-term liabilities   -     1,213,874  
Net cash used in operating activities   (53,524,389 )   (62,434,546 )
Patent costs (541,686 ) (117,992 )
Purchase of fixed assets (307,714 ) (15,559 )
Payment of security deposit   (14,036 )   -  
Net cash used in investing activities   (863,436 )   (133,551 )
Proceeds from sale of common stock, net of costs 134,863,475 91,374,649
Proceeds from exercise of warrants 1,373,000 366,000
Proceeds from exercise of options   979,060     589,829  
Net cash provided by financing activities   137,215,535     92,330,478  
Increase in cash 82,827,710 29,762,381
Cash, beginning of period   64,706,355     51,361,607  
Cash, end of period $ 147,534,065   $ 81,123,988  

Source: TherapeuticsMD, Inc.

TherapeuticsMD, Inc.
Investor Contact:
David DeLucia, 561-961-1900
Director, Investor Relations
Media Contact:
Ami Knoefler, 650-739-9952